LEADER 00000cam  2200913Ia 4500 
001    184942575 
003    OCoLC 
005    20210611123257.9 
006    m     o  d         
007    cr cn||||||||| 
008    071220s2007    enka    oab   001 0 eng d 
020    9781846284281 
020    1846284287 
020    9781846284274 
020    1846284279 
020    6610817359 
020    9786610817351 
024 7  10.1007/978-1-84628-428-1 
035    (OCoLC)184942575|z(OCoLC)159934092|z(OCoLC)228153875
       |z(OCoLC)228153876|z(OCoLC)239716551|z(OCoLC)320971197
       |z(OCoLC)401467001|z(OCoLC)613450403|z(OCoLC)648168344
       |z(OCoLC)664271592|z(OCoLC)698454049|z(OCoLC)756538645
       |z(OCoLC)880110086|z(OCoLC)985058254|z(OCoLC)994747490
       |z(OCoLC)1005829462|z(OCoLC)1019998131|z(OCoLC)1035701483
       |z(OCoLC)1044208423|z(OCoLC)1044210648|z(OCoLC)1044579386
       |z(OCoLC)1056310115|z(OCoLC)1056321611|z(OCoLC)1056402299
       |z(OCoLC)1060827926|z(OCoLC)1066471809|z(OCoLC)1067011487
       |z(OCoLC)1073053481|z(OCoLC)1078854757|z(OCoLC)1086927601
       |z(OCoLC)1097299789|z(OCoLC)1105592831|z(OCoLC)1110737220 
035    Springer Medicine eBooks 2007 English+International 
035    All EBSCO eBooks 
037    978-1-84628-427-4|bSpringer|nhttp://www.springerlink.com 
040    GW5XE|beng|epn|cGW5XE|dGW5XE|dYDXCP|dTEX|dIDEBK|dOCLCQ
       |dN$T|dMUQ|dCEF|dOTZ|dLGG|dDKU|dCNTRU|dE7B|dMNU|dYNG
       |dEBLCP|dOCLCQ|dGBVCP|dA7U|dOCLCQ|dOCLCA|dOCLCF|dOCLCQ
       |dAZU|dISOBC|dUV0|dSLY|dCOO|dTPH|dOCLCQ|dOCLCO|dOCLCQ|dLVT
       |dOCLCO|dVT2|dOCLCQ|dUAB|dOCLCO|dESU|dOCLCQ|dOCLCO|dOCLCA
       |dCASUM|dSTF|dOCLCQ|dU3W|dAU@|dOCLCO|dWYU|dMERER|dOCLCO
       |dOCLCA|dYOU|dOCLCQ|dOCLCO|dCANPU|dOCLCA|dOCLCQ|dOCLCA
       |dLEAUB|dW2U|dOCLCO|dUKAHL|dOCLCQ|dOCLCO|dWURST|dOCLCQ
       |dOCLCA|dOCLCQ 
049    txum 
050  4 RC889|b.C363 2007eb 
072  7 HEA|x045000|2bisacsh 
072  7 MJS|2bicssc 
082 04 616.69220610724|222eb 
100 1  Carson, Culley C.,|cIII|q(Culley Clyde),|d1945- 
245 10 Key clinical trials in erectile dysfunction /|cCulley C. 
       Carson. 
260    London :|bSpringer,|c©2007. 
300    1 online resource (x, 79 pages) :|billustrations 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    text file 
347    |bPDF 
504    Includes bibliographical references and index. 
505 0  Cover -- Contents -- 1. The Earliest Carefully Controlled 
       Clinical Trial Evaluating Oral Pharmacotherapy (Yohimbine)
       in ED -- 1.1 Key Trial References -- 1.2 Importance of 
       Study -- 1.3 Study Design -- 1.4 Key Results -- 1.5 
       Conclusions from Original Reports -- 1.6 Strengths -- 1.7 
       Weaknesses -- 1.8 Relevance -- 2. A Description of the 
       Pioneering Work That Led to the First Approved Agents for 
       ED: Giles Brindley, the Needle, and the Penis 
       (Phenoxybenzamine) -- 2.1 Key Trial References -- 2.2 
       Importance of Study -- 2.3 Study Design -- 2.4 Key Results
       -- 2.5 Conclusions from Original Reports -- 2.6 Strengths 
       -- 2.7 Weaknesses -- 2.8 Relevance -- 3. The Pivotal Study
       Showing That Intracorporal Injection of Vasoactive Agents 
       (Papaverine or Phenoxybenzamine) Was Effective 
       Pharmacotherapy -- 3.1 Key Trial References -- 3.2 
       Importance of Study -- 3.3 Study Design -- 3.4 Key Results
       -- 3.5 Conclusions from Original Reports -- 3.6 Strengths 
       -- 3.7 Weaknesses -- 3.8 Relevance -- 4. The First Placebo
       -Controlled Study on the Benefits of Intracorporal 
       Administration of Vasorelaxant Agents to ED Patients 
       (Papaverine/Phentolamine Combination) -- 4.1 Key Trial 
       References -- 4.2 Importance of Study -- 4.3 Study Design 
       -- 4.4 Key Results -- 4.5 Conclusions from Original 
       Reports -- 4.6 Strengths -- 4.7 Weaknesses -- 4.8 
       Relevance -- 5. Representative Study on the Use of 
       Yohimbine in the Treatment of Organic ED -- 5.1 Key Trial 
       References -- 5.2 Importance of Study -- 5.3 Study Design 
       -- 5.4 Key Results -- 5.5 Conclusions from Original 
       Reports -- 5.6 Strengths -- 5.7 Weaknesses -- 5.8 
       Relevance -- 6. Defining the Therapeutic Ratio for 
       Intracavernosal Administration of Prostaglandin E<sub>1</
       sub> (Alprostadil) -- 6.1 Key Trial References -- 6.2 
       Study Funding -- 6.3 Importance of Study -- 6.4 Study 
       Design -- 6.5 Key Results -- 6.6 Conclusions from Original
       Reports -- 6.7 Strengths -- 6.8 Weaknesses -- 6.9 
       Relevance -- 7. An Elegant Long-Term Trial Assessing the 
       Clinical Profile of Intracavernosal Prostaglandin E<sub>1<
       /sub> (Alprostadil) -- 7.1 Key Trial References -- 7.2 
       Importance of Study -- 7.3 Study Design -- 7.4 Key Results
       -- 7.5 Conclusions from Original Reports -- 7.6 Strengths 
       -- 7.7 Weaknesses -- 7.8 Relevance -- 8. Evaluation of 
       Novel Combination (Vasoactive Intestinal Polypeptide and 
       Phentolamine) as Intracavernosal Therapy -- 8.1 Key Trial 
       References -- 8.2 Study Funding -- 8.3 Importance of Study
       -- 8.4 Study Design -- 8.5 Key Results -- 8.6 Conclusions 
       from Original Reports -- 8.7 Strengths -- 8.8 Weaknesses -
       - 8.9 Relevance -- 9. Now-Classic Study on the Use of 
       Intraurethral Prostaglandin E<sub>1</sub> (Alprostadil) --
       9.1 Key Trial References -- 9.2 Study Funding -- 9.3 
       Importance of Study -- 9.4 Study Design -- 9.5 Key Results
       -- 9.6 Conclusions from Original Reports -- 9.7 Strengths 
       -- 9.8 Weaknesse. 
506    Available only to authorized UTEP users. 
520 1  "This book represents a critical appraisal of the major 
       clinical trials that have had a significant impact on 
       clinical research and practice during the last decade. 
       Each trial follows a strict format, starting with 
       reference to the original source of publication, details 
       on the key investigators and their methods of research. 
       The strengths and weaknesses of each trial are discussed, 
       as well as their influence on clinical practice. This is 
       the first book to bring together in a single volume a 
       critical review of all the major trials in ED." "Key 
       Clinical Trials in Erectile Dysfunction is a reference for
       both clinicians and research workers in urology, sexual 
       dysfunction and related disorders."--Jacket 
588 0  Print version record. 
650  0 Impotence|xChemotherapy|vAbstracts. 
650  0 Clinical trials|vAbstracts. 
650 12 Erectile Dysfunction|xhistory. 
650 22 Clinical Trials as Topic|xhistory. 
650 22 Vasodilator Agents|xhistory. 
653 00 geneeskunde 
653 00 medicine 
653 00 volksgezondheid 
653 00 public health 
653 00 geschiedenis 
653 00 history 
653 00 urinestelsel 
653 00 urinary system 
653 10 Medicine (General) 
653 10 Geneeskunde (algemeen) 
655  2 Abstracts. 
655  7 Abstracts.|2fast|0(OCoLC)fst01423683 
655  7 Abstracts.|2lcgft 
773 0  |tSpringer e-books 
776 08 |iPrint version:|aCarson, Culley C.|tKey clinical trials 
       in erectile dysfunction.|dLondon : Springer, ©2007
       |z9781846284274|z1846284279|w(DLC)  2006923813
       |w(OCoLC)75714007 
856 40 |uhttp://0-link.springer.com.lib.utep.edu/10.1007/978-1-
       84628-428-1|zTo access this resource 
856 40 |uhttp://0-search.ebscohost.com.lib.utep.edu/
       login.aspx?direct=true&scope=site&db=nlebk&AN=196829|zTo 
       access this resource 
LOCATION CALL # STATUS
 Internet  Electronic Book    AVAILABLE